Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.59 |
| ▸ | GSK3B | P49841 | 9/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1185872 | 0.82 | GSR (0.61) | GSRMMP2MMP9MMP8ENPP2 | |
| SCHEMBL5058142 | 0.82 | GSR (0.61) | GSRMMP2MMP9MMP8ENPP2 | |
| SCHEMBL28990483 | 0.80 | GSR (0.59) | GSRMMP2MMP9MMP8ENPP2 | |
| SCHEMBL8233398 | 0.80 | GSR (0.59) | GSRMMP2MMP9MMP8ENPP2 | |
| SCHEMBL26181037 | 0.80 | PTPN1 (0.59) | GSRGSK3BPTPN1 | |
| SCHEMBL15556865 | 0.80 | GSR (0.59) | GSRMMP2MMP9MMP8ENPP2 | |
| SCHEMBL3642480 | 0.80 | CA2 (0.59) | GSK3BPTPN1 | |
| SCHEMBL16923800 | 0.80 | GSR (0.59) | GSRMMP2MMP9MMP8ENPP2 | |
| SCHEMBL22584909 | 0.80 | GSR (0.59) | GSRGSK3BMMP2MMP9MMP8 | |
| SCHEMBL3144401 | 0.80 | GSK3B (0.59) | GSRGSK3BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 407 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3958980-B1 | TARGETED NOVEL TRIAZOLOTHIADIAZINE DERIVATIVES FOR THE TREATMENT OF LUNG CANCER | ANADOLU UNIV (TR) | 2023-11-15 | — | — | EP | claimed |
| EP-3958980-A1 | TARGETED NOVEL TRIAZOLOTHIADIAZINE DERIVATIVES FOR THE TREATMENT OF LUNG CANCER | Anadolu Universitesi (TR) | 2022-03-02 | — | — | EP | claimed |
| WO-2021257020-A1 | TARGETED NOVEL TRIAZOLOTHIADIAZINE DERIVATIVES FOR THE TREATMENT OF LUNG CANCER | ANADOLU ÜNİVERSİTESİ (TR) | 2021-12-23 | — | — | WO | claimed |
| CN-109134318-B | Preparation method of 4-methylsulfonyl acetophenone and α -bromo-4-methylsulfonyl acetophenone | 江苏美迪克化学品有限公司 | 2020-04-17 | — | — | CN | claimed |
| CN-109134318-A | A kind of preparation method of 4- mesyl acetophenone and the bromo- 4- mesyl acetophenone of α- | 江苏美迪克化学品有限公司 | 2019-01-04 | — | — | CN | claimed |
| CN-108864003-A | A kind of preparation method of imrecoxib intermediate and imrecoxib | 江苏美迪克化学品有限公司 | 2018-11-23 | — | — | CN | claimed |
| EP-4743081-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | Pretzel Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4200297-B1 | IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12486267-B2 | Imidazo[1,2-A]pyridine and [1,2,4]triazolo[1,5-A]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4139286-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | disclosed |
| WO-2025019407-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | PRETZEL THERAPEUTICS, INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| CN-118994063-A | Novel method for synthesizing eremophilne intermediate | 上海博悦生物科技有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-112839942-B | 1,3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same | 株式会社 钟根堂 | 2024-08-23 | — | — | CN | disclosed |
| US-4636509-A | Substituted pyrimidin-2-ones, the salts thereof, processes for their preparation, pharmaceutical compositions containing them and a method therefor | GLAXO GROUP LIMITED (GB) | 1987-01-13 | — | — | US | disclosed |
| EP-0044704-B1 | SUBSTITUTED PYRIMIDIN-2-ONES, THE SALTS THEREOF, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 1986-05-07 | — | — | EP | disclosed |
| EP-0044704-A1 | Substituted pyrimidin-2-ones, the salts thereof, processes for their preparation, and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1982-01-27 | — | — | EP | disclosed |
| EP-0005783-B1 | IMIDAZO (2.1-B)-(1.3.4)-THIADIAZOLES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICAMENTS | BAYER AG (DE) | 1981-12-30 | — | — | EP | disclosed |
| US-4265898-A | ANTICOAGULANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-05-05 | — | — | US | disclosed |
| EP-0005783-A1 | Imidazo (2.1-b)-(1.3.4)-thiadiazoles, process for their preparation and their use in medicaments | BAYER AG (DE) | 1979-12-12 | — | — | EP | disclosed |
| US-4013692-A | ANTIINFLAMMATORY, ANTIPYRETICS, ANALGESICS | RIKER LABORATORIES, INC. (US) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486267-B2 | Imidazo[1,2-A]pyridine and [1,2,4]triazolo[1,5-A]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis | TLR9, TLR1, TLR7 | GSR 2349/4885GSK3B 1882/4885PTPN1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.